The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: a scoping review of systematic reviews and meta-analyses

Abstract

Background: The COVID-19 pandemic has disrupted cancer care, raising concerns regarding the impact of wait time, or 'lag time', on clinical outcomes. We aimed to contextualize pandemic-related lag times by mapping pre-pandemic evidence from systematic reviews and/or meta-analyses on the association between lag time to cancer diagnosis and treatment with mortality- and morbidity-related outcomes.

Methods: We systematically searched MEDLINE, EMBASE, Web of Science, and Cochrane Library of Systematic Reviews for reviews published prior to the pandemic (1 January 2010-31 December 2019). We extracted data on methodological characteristics, lag time interval start and endpoints, qualitative findings from systematic reviews, and pooled risk estimates of mortality- (i.e., overall survival) and morbidity- (i.e., local regional control) related outcomes from meta-analyses. We categorized lag times according to milestones across the cancer care continuum and summarized outcomes by cancer site and lag time interval.

Results: We identified 9,032 records through database searches, of which 29 were eligible. We classified 33 unique types of lag time intervals across 10 cancer sites, of which breast, colorectal, head and neck, and ovarian cancers were investigated most. Two systematic reviews investigating lag time to diagnosis reported different findings regarding survival outcomes among pediatric patients with Ewing's sarcomas or central nervous system tumours. Comparable risk estimates of mortality were found for lag time intervals from surgery to adjuvant chemotherapy for breast, colorectal, and ovarian cancers. Risk estimates of pathologic complete response indicated an optimal time window of 7-8 weeks for neoadjuvant chemotherapy completion prior to surgery for rectal cancers. In comparing methods across meta-analyses on the same cancer sites, lag times, and outcomes, we identified critical variations in lag time research design.

Conclusions: Our review highlighted measured associations between lag time and cancer-related outcomes and identified the need for a standardized methodological approach in areas such as lag time definitions and accounting for the waiting-time paradox. Prioritization of lag time research is integral for revised cancer care guidelines under pandemic contingency and assessing the pandemic's long-term effect on patients with cancer.

Funding: The present work was supported by the Canadian Institutes of Health Research (CIHR-COVID-19 Rapid Research Funding opportunity, VR5-172666 grant to Eduardo L. Franco). Parker Tope, Eliya Farah, and Rami Ali each received an MSc. stipend from the Gerald Bronfman Department of Oncology, McGill University.

Data availability

This is a scoping review of peer-reviewed scientific literature. Data used came from scientific manuscripts which can be accessed online. All relevant information is included in the manuscript.

Article and author information

Author details

  1. Parker Tope

    Division of Cancer Epidemiology, McGill University, Montreal, Canada
    Competing interests
    Parker Tope, received an MSc. Stipend from the Gerald Bronfman Department of Oncology, McGill University..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7903-1413
  2. Eliya Farah

    Division of Cancer Epidemiology, McGill University, Montreal, Canada
    Competing interests
    Eliya Farah, received an MSc. Stipend from the Gerald Bronfman Department of Oncology, McGill University..
  3. Rami Ali

    Division of Cancer Epidemiology, McGill University, Montreal, Canada
    Competing interests
    Rami Ali, received an MSc. Stipend from the Gerald Bronfman Department of Oncology, McGill University..
  4. Mariam El-Zein

    Division of Cancer Epidemiology, McGill University, Montreal, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5190-0370
  5. Wilson H Miller Jr.

    Department of Oncology, McGill University, Montreal, Canada
    Competing interests
    Wilson H Miller, reports grants to his institution from Merck, Canadian Institutes of Health Research, Cancer Research Society, Terry Fox Research Institute, Samuel Waxman Cancer Research Foundation, and CCSRI; consultancy for Merck, BMS, Roche, GSK, Novartis, Amgen, Mylan, EMD Serono, and Sanofi; honoraria from McGill University, JGH, BMS, Merck, Roche, GSK, Novartis, Amgen, Mylan EMD Serono, and Sanofi; payments to his institution for participation in a clinical trial within the past 2 years from BMS, Novartis, GSK, Roche, AstraZeneca, Methylgene, MedImmune, Bayer, Amgen, Merck, Incyte, Pfizer, Sanofi, Array, MiMic, Ocellaris Pharma, Astellas, Alkermes, Exelixis, VelosBio, and Genetech..
  6. Eduardo L Franco

    Division of Cancer Epidemiology, McGill University, Montreal, Canada
    For correspondence
    eduardo.franco@mcgill.ca
    Competing interests
    Eduardo L Franco, Senior editor, eLifeELF reports support for the present manuscript in the form of a grant to his institution is his name from the Canadian Institutes of Health Research and the Cancer Research Society (CIHR-COVID-558 19 Rapid Research Funding opportunity, VR5-172666 grant to Eduardo L. Franco); consultancy for Merck; a patent related to the discovery DNA methylation markers for early detection of cervical cancer".
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4409-8084

Funding

Canadian Institutes of Health Research (VR5-172666)

  • Eduardo L Franco

McGill University, Gerald Bronfman Department of Oncology (MSc Stipend)

  • Parker Tope
  • Eliya Farah
  • Rami Ali

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Tope et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,251
    views
  • 191
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Parker Tope
  2. Eliya Farah
  3. Rami Ali
  4. Mariam El-Zein
  5. Wilson H Miller Jr.
  6. Eduardo L Franco
(2023)
The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: a scoping review of systematic reviews and meta-analyses
eLife 12:e81354.
https://doi.org/10.7554/eLife.81354

Share this article

https://doi.org/10.7554/eLife.81354

Further reading

    1. Epidemiology and Global Health
    2. Medicine
    3. Microbiology and Infectious Disease
    Edited by Diane M Harper et al.
    Collection

    eLife has published the following articles on SARS-CoV-2 and COVID-19.

    1. Epidemiology and Global Health
    2. Genetics and Genomics
    Tianyu Zhao, Hui Li ... Li Chen
    Research Article

    Alzheimer’s disease (AD) is a complex degenerative disease of the central nervous system, and elucidating its pathogenesis remains challenging. In this study, we used the inverse-variance weighted (IVW) model as the major analysis method to perform hypothesis-free Mendelian randomization (MR) analysis on the data from MRC IEU OpenGWAS (18,097 exposure traits and 16 AD outcome traits), and conducted sensitivity analysis with six models, to assess the robustness of the IVW results, to identify various classes of risk or protective factors for AD, early-onset AD, and late-onset AD. We generated 400,274 data entries in total, among which the major analysis method of the IVW model consists of 73,129 records with 4840 exposure traits, which fall into 10 categories: Disease, Medical laboratory science, Imaging, Anthropometric, Treatment, Molecular trait, Gut microbiota, Past history, Family history, and Lifestyle trait. More importantly, a freely accessed online platform called MRAD (https://gwasmrad.com/mrad/) has been developed using the Shiny package with MR analysis results. Additionally, novel potential AD therapeutic targets (CD33, TBCA, VPS29, GNAI3, PSME1) are identified, among which CD33 was positively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. TBCA and VPS29 were negatively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. GNAI3 and PSME1 were negatively associated with the main outcome traits of AD, as well as with LOAD, but had no significant causal association with EOAD. The findings of our research advance our understanding of the etiology of AD.